Introduction and Key Characteristics of MGP

Matrix Gla protein (MGP) is a small, secreted protein that plays a vital role in preventing abnormal calcification of tissues such as blood vessels and cartilage (pmc.ncbi.nlm.nih.gov). The human MGP gene encodes an 84–amino acid extracellular protein belonging to the vitamin K-dependent “Gla” protein family, which is characterized by γ-carboxyglutamate (Gla) residues that bind calcium (pmc.ncbi.nlm.nih.gov). MGP is highly expressed by vascular smooth muscle cells and chondrocytes in cartilage, reflecting its key functions in the vasculature and skeletal system (pmc.ncbi.nlm.nih.gov). By inhibiting the deposition of calcium phosphate minerals in the wrong places, MGP protects arterial walls from hardening and maintains the proper development of cartilage and bone. Indeed, MGP is widely recognized as a potent local inhibitor of pathological calcification in the arterial media and other soft tissues (pmc.ncbi.nlm.nih.gov). Experimental models have firmly established its importance: mice genetically lacking MGP develop widespread calcium deposits in arteries and growth plate cartilage and die by around 6–8 weeks of age due to ruptures of calcified arteries (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In humans, loss-of-function mutations in MGP cause the rare autosomal recessive Keutel syndrome, marked by inappropriate cartilage calcification, distinctive facial features, peripheral pulmonary stenosis, and short fingers (brachydactyly) (pmc.ncbi.nlm.nih.gov). These observations underscore that the primary role of MGP is to prevent ectopic mineralization – the harmful calcification of tissues that are normally flexible.

Family and Structure: MGP is one of several Gla-containing proteins (others include osteocalcin in bone and certain coagulation factors) that require vitamin K–dependent enzymes to modify specific glutamate residues to Gla (pmc.ncbi.nlm.nih.gov). The term “Gla” reflects this modification, γ-carboxylation, which is essential for the calcium-binding function of these proteins. Human MGP is synthesized as a precursor with a signal peptide that directs its secretion outside the cell (pmc.ncbi.nlm.nih.gov). Once in the extracellular space, the mature protein comprises 84 amino acids folded with a single intrachain disulfide bond for stability (pmc.ncbi.nlm.nih.gov). Notably, MGP contains five glutamic acid residues that undergo γ-carboxylation and three serine residues that undergo phosphorylation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These post-translational modifications are critical for its activity, as discussed below. MGP predominantly resides in the extracellular matrix (ECM) of tissues – for example, in the arterial wall ECM and the cartilage matrix – where it can interact with mineral ions and matrix components (pmc.ncbi.nlm.nih.gov). A small fraction of MGP is found circulating in blood, mostly in inactive forms, but it primarily functions locally in the matrix near the cells that produce it (pmc.ncbi.nlm.nih.gov).

Post-Translational Modifications and Activation

Newly synthesized MGP is inactive until it undergoes two key post-translational modifications: γ-carboxylation of specific glutamate residues and serine phosphorylation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These modifications occur in the endoplasmic reticulum and Golgi during protein processing. Vitamin K is an essential cofactor for γ-glutamyl carboxylase, the enzyme that converts glutamate to Gla on MGP (pmc.ncbi.nlm.nih.gov). In human MGP, up to five glutamate residues (e.g. at positions 2, 37, 41, 48, and 52 of the mature protein) can be carboxylated (pmc.ncbi.nlm.nih.gov). This imparts a high density of negative charges, greatly increasing MGP’s affinity for calcium ions (pmc.ncbi.nlm.nih.gov). MGP is also phosphorylated on several serine residues (at least 3 sites, e.g. Ser^3, Ser^6, Ser^9) by a Golgi-casein kinase, and this phosphorylation is important for proper extracellular localization and function (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Fully modified active MGP is often referred to as p-cMGP (phosphorylated and carboxylated MGP) in the literature (pmc.ncbi.nlm.nih.gov). After secretion, active MGP embeds in the extracellular matrix, where it can bind mineral components and signaling molecules (pmc.ncbi.nlm.nih.gov).

Critically, both γ-carboxylation and serine phosphorylation are required for MGP’s anti-calcification activity. Biochemical studies have shown that if MGP lacks these modifications (for instance, uncarboxylated or dephosphorylated MGP), its ability to prevent calcium-phosphate crystallization drops dramatically (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Schurgers et al. (2007) demonstrated this by testing fragments of MGP in a cell culture calcification assay: only the fully carboxylated or phosphorylated forms of MGP (or their modified peptide fragments) could inhibit calcification, whereas unmodified fragments had no effect (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Gamma-carboxylation bestows MGP with multiple Gla residues that bind calcium ions avidly, effectively sequestering Ca^2+ and interfering with crystal formation (pmc.ncbi.nlm.nih.gov). Phosphorylation of MGP also appears to enhance its calcium-binding capacity and may influence how MGP attaches to the extracellular matrix (pmc.ncbi.nlm.nih.gov). Consistent with these requirements, the inactive form of MGP – often measured in blood as dephosphorylated-uncarboxylated MGP (dp-ucMGP) – tends to be elevated when vitamin K levels are low and is associated with a higher burden of vascular calcification (pubmed.ncbi.nlm.nih.gov). In other words, without sufficient vitamin K to carboxylate MGP (as in patients on warfarin therapy or with dietary deficiency), MGP remains in an inactive form that cannot protect tissues from calcification (pubmed.ncbi.nlm.nih.gov). This connection is supported by clinical and experimental evidence: for example, long-term warfarin (a vitamin K antagonist) use correlates with accelerated arterial and valve calcification, and warfarin treatment in animal models causes rapid calcium deposition in arteries within weeks (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Primary Function: Inhibition of Ectopic Calcification

The foremost function of MGP is to serve as a calcification inhibitor in the extracellular matrix, preventing the inappropriate deposition of calcium hydroxyapatite (the mineral found in bone) in soft tissues. Several lines of evidence demonstrate MGP’s critical role in restraining calcification:

• Genetic knockout in mice: MGP-deficient (Mgp^-/-) mice develop massive arterial and cartilage calcification soon after birth. The mineralization in arteries leads to arterial stiffening and rupture, and mice typically die by ~6–8 weeks of age (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, these calcifications occur in the medial layer of arteries without the need for atherosclerotic plaque, indicating that loss of MGP triggers a direct osteogenic transformation of vascular tissues (pmc.ncbi.nlm.nih.gov). This seminal finding (Luo et al., Nature 1997) established MGP as an endogenous inhibitor of vascular and cartilage calcification.

• Human mutations (Keutel syndrome): Rare bi-allelic mutations in the MGP gene cause Keutel syndrome, a genetic disorder characterized by abnormal calcification of cartilage (evident in the trachea, rib cage, nose, ears), vascular abnormalities (peripheral pulmonary artery stenosis), hearing loss, and facial dysmorphisms (pmc.ncbi.nlm.nih.gov). To date only a few dozen cases have been reported, but all confirmed cases show mineralization of cartilage on imaging, confirming that functional MGP is required to keep cartilage flexible and free of mineral deposits (pmc.ncbi.nlm.nih.gov). Keutel syndrome patients also often have brachydactyly (short digits due to premature cartilage calcification in growth plates) (pmc.ncbi.nlm.nih.gov). This human syndrome mirrors the phenotype of MGP-knockout mice and underscores MGP’s physiological role in preventing ectopic calcification in people.

• Pharmacologic inactivation (vitamin K antagonism): Inhibition of MGP’s activation through vitamin K antagonists like warfarin provides further evidence of its function. Warfarin-treated experimental animals rapidly develop arterial calcification, particularly in elastic arteries, due to the production of under-carboxylated MGP (pmc.ncbi.nlm.nih.gov). For example, one study showed rats on warfarin exhibited calcification of the elastic lamellae in their arteries within 1–2 weeks (pmc.ncbi.nlm.nih.gov). Clinically, patients on long-term warfarin have a higher incidence of vascular and valvular calcification, and imaging studies have found increased coronary artery calcium in warfarin users (pmc.ncbi.nlm.nih.gov). These effects are attributable to MGP remaining in its inactive uncarboxylated form (ucMGP) when vitamin K is blocked (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). High circulating levels of dp-ucMGP are observed in such patients and correlate with greater vascular calcification burden (pubmed.ncbi.nlm.nih.gov). Encouragingly, supplementation with vitamin K in vitro or in animal models can restore MGP’s carboxylation and slow the progression of calcification (pubmed.ncbi.nlm.nih.gov), a strategy now being tested in clinical trials for chronic kidney disease and other calcification-prone conditions.

Biochemical Mechanisms: MGP employs a multifaceted strategy to inhibit calcification at the molecular level. After being secreted by cells into the extracellular matrix, MGP can directly bind mineral ions and crystal surfaces and also modulate cell signaling pathways that drive calcification. Key mechanisms include:

• Mineral binding and crystal inhibition: The γ-carboxylated glutamate residues (Gla) in MGP form strong ionic bonds with calcium ions (pmc.ncbi.nlm.nih.gov). This allows MGP to adsorb to nascent hydroxyapatite crystals or to free calcium and phosphate, blocking crystal growth and propagation in soft tissues. Experimental data show that fully carboxylated MGP can actually coat the surface of developing mineral crystals and even help break them apart (a process sometimes described as “absorbing” or disassembling the crystals) (pmc.ncbi.nlm.nih.gov). In contrast, MGP that is not carboxylated or not phosphorylated has a greatly reduced ability to interfere with hydroxyapatite formation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). By essentially “soaking up” local calcium, phosphate, and initial crystal nuclei, active MGP prevents these components from coalescing into stable bone-like deposits in the wrong location (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This mechanism is often compared to other circulating inhibitors like fetuin-A; together, MGP and fetuin-A act as a front-line defense against pathological calcification by binding mineral ions and facilitating their safe removal (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

• Sequestration of pro-osteogenic signals: MGP also guards against calcification by binding to and inhibiting bone morphogenetic proteins (BMPs) – cytokines that trigger bone formation pathways. In particular, MGP has been shown to bind BMP-2, a potent inducer of osteogenic differentiation in vascular smooth muscle cells (VSMCs) (pmc.ncbi.nlm.nih.gov). BMP-2 normally activates the BMP receptor/SMAD signaling cascade in VSMCs, up-regulating the transcription factor Runx2 and other bone-related genes that cause the cells to behave like osteoblasts (pmc.ncbi.nlm.nih.gov). By sequestering BMP-2 and BMP-4, MGP prevents these ligands from engaging their receptors on cells (pmc.ncbi.nlm.nih.gov). In effect, active MGP acts as a decoy, curtailing BMP-driven signals that would otherwise promote the deposition of a bone matrix in the vessel wall. This mechanism was demonstrated by Zebboudj et al.: they found that adding MGP could dose-dependently block BMP-2’s ability to induce bone gene expression and calcification in a vascular cell culture model (pmc.ncbi.nlm.nih.gov). Thus, MGP helps maintain vascular smooth muscle in a contractile, healthy state by neutralizing BMP signals that prompt a switch to an osteogenic program.

Through these mechanisms – direct mineral interaction and modulation of osteogenic signaling – MGP effectively suppresses the formation of ectopic calcifications. It is worth noting that MGP does not remove calcium from the body entirely; rather, it ensures that calcium will crystallize only where it is intended (in bones and teeth) and not in soft tissues. In bones, other proteins like osteocalcin and the controlled environment allow mineralization to proceed, whereas in soft tissues MGP is one of the dominant inhibitors keeping them calcification-free (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Biological Role in Tissues and Development

MGP’s activity is crucial in multiple tissues, primarily the vascular system and the cartilage/bone system, aligning with the sites of its highest expression.

Vascular system: In arteries, MGP is produced by vascular smooth muscle cells and deposits in the arterial wall matrix, particularly around elastic fibers. Its role here is to prevent arterial medial calcification, which is a hallmark of arteriosclerosis (vascular stiffening). When MGP is absent or inactive, calcium phosphate can infiltrate the elastic lamellae of arteries, turning them rigid and brittle (pmc.ncbi.nlm.nih.gov). This medial calcification dramatically increases arterial stiffness and can lead to life-threatening vessel rupture, as seen in MGP-null mice (pmc.ncbi.nlm.nih.gov). Even a partial reduction in MGP activity can contribute to cardiovascular pathology – for instance, patients with chronic kidney disease often have subclinical vitamin K deficiency leading to high dp-ucMGP, and this is associated with more severe vascular calcifications and arterial stiffness than in those with fully active MGP (pubmed.ncbi.nlm.nih.gov). MGP’s presence correlates inversely with calcific burden: one clinical study found that patients with calcified aortic valves had significantly lower circulating MGP levels (active form) compared to controls, suggesting insufficient MGP to inhibit calcification in valve tissues (pubmed.ncbi.nlm.nih.gov). Beyond simply blocking mineral deposition, MGP appears to influence the architecture of the vascular extracellular matrix. MGP-deficient arteries show fragmentation of elastic fibers and increased collagen deposition in the vessel wall (pmc.ncbi.nlm.nih.gov). This indicates that normal MGP may help maintain elastic fiber integrity or regulate matrix remodeling enzymes, thereby preserving the vessel’s elasticity (pmc.ncbi.nlm.nih.gov). There is also evidence that MGP interacts with growth factor pathways in the vasculature: loss of MGP leads to upregulation of certain pro-angiogenic factors like VEGF. In MGP-null mice, an excess of VEGF-A and its receptor VEGFR2 was observed, causing abnormal angiogenesis and hypervascularization in organs such as the kidney (pmc.ncbi.nlm.nih.gov). Researchers found arteriovenous malformations in these mice, suggesting that MGP normally helps modulate signals like VEGF to ensure proper vascular patterning during development (pmc.ncbi.nlm.nih.gov). In summary, MGP in blood vessels serves to prevent calcification and preserve normal vessel structure and function, balancing the signals that govern vascular cell differentiation and matrix organization.

Cartilage and bone: MGP is also critical in the endochondral ossification process (the formation of bone from a cartilage template). It is strongly expressed by certain chondrocytes in the growth plate – notably the proliferative zone and the late hypertrophic zone – but is low in the intermediate maturing chondrocytes (pmc.ncbi.nlm.nih.gov). This precise, biphasic expression pattern hints at MGP’s role in ensuring that mineralization of cartilage occurs at the right time and place. Studies in cell culture and animal models confirm that coordinated MGP expression is required for normal cartilage maturation: if MGP is absent when proliferative chondrocytes are maturing, these cells undergo apoptosis (premature cell death) instead of progressing to bone formation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Conversely, if MGP is overexpressed at the wrong stage (for example, kept high during the hypertrophic phase when cartilage should normally mineralize), it can block the mineralization of that cartilage matrix (pmc.ncbi.nlm.nih.gov). In an experiment using a chondrogenic cell line, adding MGP-neutralizing antibodies during the early proliferative phase caused the cartilage cells to die and prevented normal development (pmc.ncbi.nlm.nih.gov). Meanwhile, forced overexpression of MGP in late-stage chondrocytes reduced the formation of mineral, essentially stalling the conversion of cartilage to bone (pmc.ncbi.nlm.nih.gov). These findings suggest that MGP must be present at the right level during early cartilage growth to ensure cell survival, then downregulated at the point when mineralization is supposed to occur. In living organisms, MGP likely serves as a safeguard to keep the growth plate cartilage from calcifying too soon, which would prematurely stop bone growth. Only when chondrocytes reach the final hypertrophic stage and other signals (like local drop in MGP, increase in other factors) converge, does mineralization proceed in a controlled manner. Apart from growth plates, MGP is found in cartilaginous tissues like the trachea and ear/nose cartilage, where its role is to maintain long-term cartilage flexibility. In Keutel syndrome (human MGP deficiency), the calcification of these cartilages leads to respiratory issues (tracheal calcification), hearing impairment (due to calcified ear cartilage), and a characteristic nose deformity due to calcified nasal cartilage (pmc.ncbi.nlm.nih.gov). Even in bone tissue, which must mineralize, MGP is present and thought to help confine mineral to the proper extracellular matrix compartments. MGP is abundant in dentin (the calcified tissue of teeth) as well (pmc.ncbi.nlm.nih.gov), again presumably to regulate mineral growth. Overall, MGP works in concert with pro-mineralizing proteins to finely tune where and when calcification happens in the skeleton. Without MGP, mineralization becomes unrestrained, spreading into areas (arterial media, cartilage matrix) where it causes structural and functional damage.

Signaling Pathways and Interactions

MGP does not fit the profile of a classic enzyme, transporter, or receptor; instead, it functions as a secreted regulatory protein that modulates extracellular signals and matrix chemistry. In terms of biochemical pathways, the actions of MGP intersect notably with:

• Vitamin K cycle: As a vitamin K–dependent protein, MGP is part of the broader pathway of γ-carboxylation. The enzyme γ-glutamyl carboxylase in the liver and in MGP-producing cells uses reduced vitamin K (vitamin K hydroquinone) to carboxylate MGP’s glutamate residues (pmc.ncbi.nlm.nih.gov). This ties MGP to the vitamin K cycle (which also γ-carboxylates coagulation factors). Insufficient vitamin K or genetic defects in the carboxylase (or in vitamin K recycling enzymes) result in under-carboxylated MGP. For instance, rare mutations in the gene GGCX (γ-glutamyl carboxylase) or in VKOR (vitamin K epoxide reductase) can lead to a syndrome of calcification due in part to MGP inactivation (pubmed.ncbi.nlm.nih.gov). Thus, one can view MGP’s functionality as an output of the vitamin K metabolic pathway, making it a sensor of vitamin K status in tissues. Indeed, assays of circulating dp-ucMGP are being explored as biomarkers of vitamin K deficiency and vascular calcification risk (pubmed.ncbi.nlm.nih.gov).

• Bone morphogenetic protein (BMP) signaling: MGP’s ability to bind BMP-2 places it as a modulator of the BMP/TGF-β signaling pathway in the extracellular space. BMP-2 and BMP-4 are members of the TGF-β superfamily that promote osteogenesis (bone formation) and chondrogenesis. By sequestering BMPs, MGP effectively down-regulates BMP signaling in tissues like arteries and cartilage (pmc.ncbi.nlm.nih.gov). This has been shown to influence cell fate: for example, in vascular smooth muscle, active BMP signaling (via BMP-2) induces the expression of the osteogenic transcription factor Runx2 and other bone-related genes (pmc.ncbi.nlm.nih.gov). MGP curtails this pathway, thereby keeping smooth muscle cells in a non-osteogenic state. Interestingly, BMPs also cross-talk with other pathways like those governing angiogenesis; in endothelial cells, high VEGF can induce BMP-2 expression (pmc.ncbi.nlm.nih.gov). The loss of MGP leads to a scenario of unchecked BMP and VEGF activity, explaining the combination of calcification and aberrant angiogenesis seen in MGP-null animals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, MGP is an extracellular “brake” on BMP-driven ossification signals, helping maintain the correct differentiation program of cells in the vascular wall and growth plate.

• Extracellular matrix organization: Through its calcium-binding and protein-binding activities, MGP is part of the network of ECM proteins that govern calcified matrix deposition. It may not have a structural role like collagen or elastin, but by adhering to those matrix fibers and mineral targets, MGP influences processes like matrix vesicle release and crystal nucleation in the ECM. Its interaction with fetuin-A (a circulating inhibitor that also scavenges mineral) suggests MGP might work in a complex that facilitates the clearance of calcium-phosphate complexes from tissues (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, MGP’s role in elastin fiber maintenance (evidenced by elastin fragmentation when MGP is absent) hints that it might interact with elastin or protect it from calcinosis (pmc.ncbi.nlm.nih.gov). Elastic fibers in arteries are a prime site where calcification initiates when inhibitors are missing, so MGP likely localizes to elastin-rich regions to prevent calcium precipitation there.

• Growth factor signaling in fibrosis and cancer (emerging): Beyond its classic role in calcification, new research shows that MGP can influence other signaling pathways like TGF-β and Hedgehog in certain contexts. A 2023 study uncovered that in the liver, MGP helps mediate TGF-β signaling in hepatic stellate cells, which are key drivers of fibrosis in non-alcoholic steatohepatitis (NASH) (pubmed.ncbi.nlm.nih.gov). When MGP was knocked down in cultured stellate cells, the cells had a blunted response to TGF-β – showing less phosphorylation of SMAD2/3 and reduced expression of the TGF-β receptor ALK1, along with increased levels of the inhibitory SMAD6 (pubmed.ncbi.nlm.nih.gov). This suggests MGP might normally promote or fine-tune TGF-β signaling in these cells, potentially by affecting receptor availability or matrix binding of TGF-β. Consequently, MGP expression in the liver was found to correlate with the severity of fibrosis in NASH patients (pubmed.ncbi.nlm.nih.gov). In a different realm, a 2023 report highlighted MGP’s involvement in cancer biology: ovarian cancer stem cells were found to highly express MGP, which was unexpected for a protein known to prevent calcification (pubmed.ncbi.nlm.nih.gov). In that study, MGP drove a stem-like, tumor-initiating phenotype in ovarian cancer cells by activating the Hedgehog signaling pathway – specifically inducing the GLI1 transcription factor (pubmed.ncbi.nlm.nih.gov). MGP was both necessary and sufficient for maintaining cancer stemness and promoting tumor growth in mouse models, and its expression correlated with worse prognosis in ovarian cancer patients (pubmed.ncbi.nlm.nih.gov). These findings broaden the scope of pathways that MGP can interact with, hinting that MGP might bind or present growth factors outside of the calcification context as well. However, it is important to note that these emerging roles (in fibrogenesis and oncogenesis) are areas of active research and may involve co-factors or indirect mechanisms. They do illustrate that MGP has pleiotropic effects beyond mineral binding – potentially functioning in cell signaling niches by interacting with TGF-β/BMP family members or other morphogens. Still, the best-understood and primary pathway influenced by MGP is the mineralization pathway, through direct binding of calcium/phosphate and inhibition of BMP-driven osteogenic programs.

Clinical Significance and Applications

Given MGP’s central role in preventing pathological calcification, it has significant implications in human health and disease. Vascular calcification, in particular, is a major concern in cardiovascular disease, diabetes, and chronic kidney disease – conditions in which MGP’s function (or vitamin K–dependent activation) may be compromised. Researchers and clinicians are investigating MGP both as a biomarker and as a therapeutic target in these settings.

In cardiovascular medicine, the level of inactive MGP (dp-ucMGP) in blood is being evaluated as a risk indicator for calcification-related events. High dp-ucMGP suggests that a person has insufficient vitamin K to fully activate MGP, and studies have shown an association between elevated dp-ucMGP and the presence or progression of vascular calcifications (pubmed.ncbi.nlm.nih.gov). For example, one study in patients with type 2 diabetes found that those with more coronary artery calcification had significantly higher dp-ucMGP levels, linking MGP inactivity to disease severity (pubmed.ncbi.nlm.nih.gov). This has led to the idea of using dp-ucMGP measurements to gauge a patient’s vitamin K status and vascular health, and even to guide vitamin K supplementation therapy (pmc.ncbi.nlm.nih.gov). In chronic kidney disease (CKD) and end-stage renal disease, patients often have accelerated vascular calcification and low vitamin K levels; trials such as VitaVasK and RenaKvit have been conducted to test whether giving high-dose vitamin K (K1 or K2) can reduce vascular calcification in CKD by boosting MGP activity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). While results have been mixed and are still being analyzed, these trials underscore the translational interest in activating the MGP pathway as a means to protect against cardiovascular complications. Notably, unlike warfarin (which worsens calcification), newer anticoagulants (direct oral anticoagulants like rivaroxaban or dabigatran) do not inhibit vitamin K and thus do not interfere with MGP; this has prompted studies showing that warfarin, but not these newer drugs, promotes arterial and valvular calcification in animal models (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Such findings are influencing clinical thinking about long-term anticoagulation in patients at risk for calcific vasculopathy.

In the realm of genetics, diagnosis of Keutel syndrome by sequencing the MGP gene can inform clinical management (for example, monitoring and treating respiratory tract calcifications or vascular stenoses in these patients) (pmc.ncbi.nlm.nih.gov). Though rare, Keutel syndrome highlights the need for functional MGP and has spurred interest in whether more common variations in the MGP gene or its regulatory regions could contribute to susceptibility to vascular calcification or osteoporosis in the general population. Some studies have found polymorphisms in MGP associated with differences in arterial stiffness or calcification indexes, though results vary and the effect sizes are usually modest.

Beyond cardiovascular disease, measurement of MGP is being explored in other fields. For instance, in oncology, there is emerging evidence that MGP expression changes in tumors (as noted in ovarian and colorectal cancers) (pubmed.ncbi.nlm.nih.gov) (www.mdpi.com). It’s premature, but researchers have asked if MGP could serve as a biomarker in cancer – for example, one systematic review questioned whether MGP might be a useful marker for colorectal cancer detection, given that some tumors show dysregulated MGP expression (www.mdpi.com). These applications are still exploratory. On the therapeutic front, if further studies confirm that MGP drives fibrosis in NASH or contributes to cancer stem cell niches, one could envision targeting MGP or its interacting pathways. Indeed, an October 2023 editorial by liver disease experts commented that “matrix Gla protein (MGP) has emerged as a new target for fighting fibrosis” in NASH, given that reducing MGP expression in preclinical models lessened liver fibrogenesis (pmc.ncbi.nlm.nih.gov). However, such interventions would need to carefully balance the consequences in other tissues – completely inhibiting MGP systemically could risk inducing vascular calcification, so localized or pathway-specific strategies might be required.

In summary, MGP is a critical anti-calcification protein with expanding relevance in medicine. Maintaining adequate vitamin K levels (through diet or supplementation) to support MGP’s activity is a practical consideration for patients at risk of vascular calcification. MGP or its modified forms can serve as indicators of vascular health and are the subject of ongoing clinical research. Furthermore, as new roles for MGP in fibrotic diseases and cancer are uncovered, this once narrowly viewed “calcification inhibitor” is now appreciated as a more pleiotropic factor in the extracellular environment. Its study exemplifies how a deep understanding of a gene’s primary function (in this case, regulating biomineralization) can open doors to insights in diverse biological processes and disease states.

References: (Publication dates and sources are included in citations throughout the text)

Citations

1. AnnotationURLCitation(end_index=362, start_index=210, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
2. AnnotationURLCitation(end_index=745, start_index=569, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=Matrix%20Gla%20protein%20%28MGP%29,in%20the%20maturing%2Fearly%20hypertrophic%20chondrocytes')
3. AnnotationURLCitation(end_index=1042, start_index=902, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=coagulation%20factors%2C%20osteocalcin%2C%20and%20the,11')
4. AnnotationURLCitation(end_index=1515, start_index=1363, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
5. AnnotationURLCitation(end_index=1906, start_index=1754, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
6. AnnotationURLCitation(end_index=2026, start_index=1907, title='Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10685148/#:~:text=MGP%20is%20a%20small%20secretory,7')
7. AnnotationURLCitation(end_index=2443, start_index=2274, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
8. AnnotationURLCitation(end_index=3018, start_index=2842, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=Matrix%20Gla%20protein%20%28MGP%29,in%20the%20maturing%2Fearly%20hypertrophic%20chondrocytes')
9. AnnotationURLCitation(end_index=3433, start_index=3257, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=Matrix%20Gla%20protein%20%28MGP%29,in%20the%20maturing%2Fearly%20hypertrophic%20chondrocytes')
10. AnnotationURLCitation(end_index=3721, start_index=3573, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=match%20at%20L100%20single%20disulfide,carboxylation%20converts')
11. AnnotationURLCitation(end_index=4001, start_index=3857, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=residues%20that%20could%20be%20phosphorylated,MGP%20has%20a')
12. AnnotationURLCitation(end_index=4135, start_index=4002, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=MGP%20is%20composed%20of%2084,carboxylated%20MGP')
13. AnnotationURLCitation(end_index=4593, start_index=4435, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=two%20posttranslational%20modifications%2C%20serine%20phosphorylation,ECM')
14. AnnotationURLCitation(end_index=4898, start_index=4756, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=cMGP%29.%20Subsequently%2C%20dp,cMGP%20moves%20into%20the')
15. AnnotationURLCitation(end_index=5291, start_index=5133, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=two%20posttranslational%20modifications%2C%20serine%20phosphorylation,ECM')
16. AnnotationURLCitation(end_index=5434, start_index=5292, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=cMGP%29.%20Subsequently%2C%20dp,cMGP%20moves%20into%20the')
17. AnnotationURLCitation(end_index=5792, start_index=5640, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
18. AnnotationURLCitation(end_index=6066, start_index=5922, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=residues%20that%20could%20be%20phosphorylated,MGP%20has%20a')
19. AnnotationURLCitation(end_index=6332, start_index=6168, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=tissue%20calcification.%20%CE%B3,a%20negatively%20charged%20protein%2C%20mostly')
20. AnnotationURLCitation(end_index=6690, start_index=6548, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=cMGP%29.%20Subsequently%2C%20dp,cMGP%20moves%20into%20the')
21. AnnotationURLCitation(end_index=6862, start_index=6691, title='Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: evidence for an uptake mechanism for serum fetuin - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15280384/#:~:text=microsomal%20fractions%20obtained%20from%20the,uptake%20and%20secretion%20by%20proliferating')
22. AnnotationURLCitation(end_index=7127, start_index=6985, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=cMGP%29.%20Subsequently%2C%20dp,cMGP%20moves%20into%20the')
23. AnnotationURLCitation(end_index=7412, start_index=7254, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=two%20posttranslational%20modifications%2C%20serine%20phosphorylation,ECM')
24. AnnotationURLCitation(end_index=7914, start_index=7733, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=vascular%20calcification%29%20%28Nigwekar%20et%20al,MGP%20integrates%20calcium%20and%20phosphate')
25. AnnotationURLCitation(end_index=8047, start_index=7915, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=%28%CE%B3,This%20function%20of%20MGP%20inhibits')
26. AnnotationURLCitation(end_index=8477, start_index=8329, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=could%20be%20%CE%B3,of%20glutamate%20residues%20increases%20the')
27. AnnotationURLCitation(end_index=8612, start_index=8478, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=fragment%20,This%20function%20of%20MGP%20inhibits')
28. AnnotationURLCitation(end_index=8942, start_index=8778, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=tissue%20calcification.%20%CE%B3,a%20negatively%20charged%20protein%2C%20mostly')
29. AnnotationURLCitation(end_index=9215, start_index=9083, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=%28%CE%B3,This%20function%20of%20MGP%20inhibits')
30. AnnotationURLCitation(end_index=9638, start_index=9476, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
31. AnnotationURLCitation(end_index=10010, start_index=9848, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
32. AnnotationURLCitation(end_index=10419, start_index=10300, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=,vitamin%20K%20is%20necessary%20for')
33. AnnotationURLCitation(end_index=10511, start_index=10420, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=,Google')
34. AnnotationURLCitation(end_index=11285, start_index=11133, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
35. AnnotationURLCitation(end_index=11405, start_index=11286, title='Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10685148/#:~:text=MGP%20is%20a%20small%20secretory,7')
36. AnnotationURLCitation(end_index=11722, start_index=11612, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=2013%20%29.%20As%20MGP,13')
37. AnnotationURLCitation(end_index=12372, start_index=12203, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
38. AnnotationURLCitation(end_index=12762, start_index=12593, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
39. AnnotationURLCitation(end_index=13065, start_index=12896, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
40. AnnotationURLCitation(end_index=13651, start_index=13560, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=,Google')
41. AnnotationURLCitation(end_index=13874, start_index=13783, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=,Google')
42. AnnotationURLCitation(end_index=14226, start_index=14066, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=Given%20the%20widespread%20use%20of,with%20suspected%20CAD%20who%20underwent')
43. AnnotationURLCitation(end_index=14503, start_index=14346, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=van%20Gorp%20et%20al,ucMGP%20significantly%20correlates%20with%20vascular')
44. AnnotationURLCitation(end_index=14664, start_index=14504, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=Given%20the%20widespread%20use%20of,with%20suspected%20CAD%20who%20underwent')
45. AnnotationURLCitation(end_index=14955, start_index=14793, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
46. AnnotationURLCitation(end_index=15270, start_index=15108, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
47. AnnotationURLCitation(end_index=16023, start_index=15859, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=tissue%20calcification.%20%CE%B3,a%20negatively%20charged%20protein%2C%20mostly')
48. AnnotationURLCitation(end_index=16582, start_index=16401, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=vascular%20calcification%29%20%28Nigwekar%20et%20al,MGP%20integrates%20calcium%20and%20phosphate')
49. AnnotationURLCitation(end_index=16857, start_index=16725, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=%28%CE%B3,This%20function%20of%20MGP%20inhibits')
50. AnnotationURLCitation(end_index=17039, start_index=16858, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=vascular%20calcification%29%20%28Nigwekar%20et%20al,MGP%20integrates%20calcium%20and%20phosphate')
51. AnnotationURLCitation(end_index=17393, start_index=17229, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=tissue%20calcification.%20%CE%B3,a%20negatively%20charged%20protein%2C%20mostly')
52. AnnotationURLCitation(end_index=17575, start_index=17394, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=vascular%20calcification%29%20%28Nigwekar%20et%20al,MGP%20integrates%20calcium%20and%20phosphate')
53. AnnotationURLCitation(end_index=17930, start_index=17807, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=al,and%20phosphate%20ions%20from%20the')
54. AnnotationURLCitation(end_index=18069, start_index=17931, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=%28%CE%B1_%7B2%7D,and%20phosphate%20ions%20from%20the')
55. AnnotationURLCitation(end_index=18529, start_index=18416, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=morphogenetic%20protein,2003')
56. AnnotationURLCitation(end_index=18841, start_index=18728, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=morphogenetic%20protein,2003')
57. AnnotationURLCitation(end_index=19089, start_index=18946, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
58. AnnotationURLCitation(end_index=19596, start_index=19453, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
59. AnnotationURLCitation(end_index=20435, start_index=20324, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=previously%20regarded,Hence')
60. AnnotationURLCitation(end_index=20609, start_index=20436, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=There%20are%20multiple%20mechanisms%20that,network%20of%20vascular%20calcification%20with')
61. AnnotationURLCitation(end_index=21335, start_index=21244, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=,Google')
62. AnnotationURLCitation(end_index=21598, start_index=21479, title='Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10685148/#:~:text=MGP%20is%20a%20small%20secretory,7')
63. AnnotationURLCitation(end_index=22092, start_index=21930, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
64. AnnotationURLCitation(end_index=22524, start_index=22373, title='Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19350115/#:~:text=AVC%20in%20the%20patients%20was,Multifactorial%20analysis%20revealed%20a')
65. AnnotationURLCitation(end_index=22913, start_index=22770, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
66. AnnotationURLCitation(end_index=23213, start_index=23070, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
67. AnnotationURLCitation(end_index=23683, start_index=23548, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=that%20reduction%20in%20active%20MGP,2%20%28VEGFR2')
68. AnnotationURLCitation(end_index=23999, start_index=23864, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=that%20reduction%20in%20active%20MGP,2%20%28VEGFR2')
69. AnnotationURLCitation(end_index=24662, start_index=24537, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=glutamic%20acid%20%28Gla%29%20residues,11')
70. AnnotationURLCitation(end_index=25236, start_index=25095, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=growth%20plate,After%20stable%20transfection%20of%20ATDC5')
71. AnnotationURLCitation(end_index=25395, start_index=25237, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=the%20cell%20line%20with%20insulin%2C,has%20no%20effect%20on%20chondrocyte')
72. AnnotationURLCitation(end_index=25791, start_index=25609, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=chondrocyte%20viability%20or%20mineralization,required%20for%20chondrocyte%20differentiation%20and')
73. AnnotationURLCitation(end_index=26139, start_index=25981, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=the%20cell%20line%20with%20insulin%2C,has%20no%20effect%20on%20chondrocyte')
74. AnnotationURLCitation(end_index=26481, start_index=26299, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=chondrocyte%20viability%20or%20mineralization,required%20for%20chondrocyte%20differentiation%20and')
75. AnnotationURLCitation(end_index=27628, start_index=27459, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
76. AnnotationURLCitation(end_index=27984, start_index=27844, title='Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2196415/#:~:text=coagulation%20factors%2C%20osteocalcin%2C%20and%20the,11')
77. AnnotationURLCitation(end_index=29058, start_index=28906, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=Matrix%20Gla%20protein%20,caused%20by%20excessive%20expression%20of')
78. AnnotationURLCitation(end_index=29577, start_index=29461, title='Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: evidence for an uptake mechanism for serum fetuin - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15280384/#:~:text=Skip%20to%20main%20page%20content,MGP')
79. AnnotationURLCitation(end_index=30012, start_index=29850, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
80. AnnotationURLCitation(end_index=30555, start_index=30412, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
81. AnnotationURLCitation(end_index=30884, start_index=30771, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=morphogenetic%20protein,2003')
82. AnnotationURLCitation(end_index=31288, start_index=31127, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=al.%2C%202013%29.%20Indeed%2C%20VEGF,deposition%20in%20MGP%20knockout%20mice')
83. AnnotationURLCitation(end_index=31618, start_index=31457, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=al.%2C%202013%29.%20Indeed%2C%20VEGF,deposition%20in%20MGP%20knockout%20mice')
84. AnnotationURLCitation(end_index=31754, start_index=31619, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=that%20reduction%20in%20active%20MGP,2%20%28VEGFR2')
85. AnnotationURLCitation(end_index=32679, start_index=32536, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=match%20at%20L154%20al,and%20phosphate%20ions%20from%20the')
86. AnnotationURLCitation(end_index=32803, start_index=32680, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=al,and%20phosphate%20ions%20from%20the')
87. AnnotationURLCitation(end_index=33130, start_index=32987, title='The vascular protective effect of matrix Gla protein during kidney injury - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11285670/#:~:text=et%20al,of%20arteries%2C%20further%20increasing%20vascular')
88. AnnotationURLCitation(end_index=33877, start_index=33725, title='Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/37611662/#:~:text=Mgp%20was%20found%20to%20be,suggesting%20relevance%20to%20human%20disease')
89. AnnotationURLCitation(end_index=34276, start_index=34124, title='Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/37611662/#:~:text=Mgp%20was%20found%20to%20be,suggesting%20relevance%20to%20human%20disease')
90. AnnotationURLCitation(end_index=34705, start_index=34551, title='Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/37611662/#:~:text=blunted%20response%20to%20TGF,suggesting%20relevance%20to%20human%20disease')
91. AnnotationURLCitation(end_index=35091, start_index=34922, title='Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36977707/#:~:text=profiled%20the%20transcriptome%20of%20OCSC,shortening%20tumor%20latency%20and%20increasing')
92. AnnotationURLCitation(end_index=35446, start_index=35285, title='Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36977707/#:~:text=the%20peritoneal%20microenvironment%20as%20a,the%20clinical%20relevance%20of%20our')
93. AnnotationURLCitation(end_index=35800, start_index=35640, title='Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36977707/#:~:text=initiation%20in%20OC%20mouse%20models%2C,stemness%20and%20in%20tumor%20initiation')
94. AnnotationURLCitation(end_index=37579, start_index=37417, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
95. AnnotationURLCitation(end_index=37941, start_index=37779, title='Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32977548/#:~:text=Matrix%20gla%20protein%20,artery%20and%20valve%20calcification%2C%20atherosclerosis')
96. AnnotationURLCitation(end_index=38293, start_index=38112, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=modifications%2C%20various%20species%20of%20MGP,implications%20to%20coronary%20plaque%20stability')
97. AnnotationURLCitation(end_index=38780, start_index=38614, title='Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9664584/#:~:text=patients%3A%20the%20VitaVasK%20randomized%20controlled,4%7D%2C%20Markus%20Ketteler')
98. AnnotationURLCitation(end_index=38902, start_index=38781, title='Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8406073/#:~:text=of%20the%20double,4%7D%2C%20Christian')
99. AnnotationURLCitation(end_index=39545, start_index=39445, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=calcification,88')
100. AnnotationURLCitation(end_index=39703, start_index=39546, title='Role of Matrix Gla Protein in the Complex Network of Coronary Artery Disease: A Comprehensive Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8398385/#:~:text=van%20Gorp%20et%20al,ucMGP%20significantly%20correlates%20with%20vascular')
101. AnnotationURLCitation(end_index=40229, start_index=40060, title='A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6006623/#:~:text=Keutel%20syndrome%20is%20caused%20by,identified%20a%20novel%20pathogenic%20homozygous')
102. AnnotationURLCitation(end_index=41049, start_index=40922, title='Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36977707/#:~:text=,stimulation%20of%20Hedgehog%20signaling%2C%20in')
103. AnnotationURLCitation(end_index=41200, start_index=41050, title='Matrix Gla Protein—A New Marker for Colorectal Cancer Detection? A Systematic Review', type='url_citation', url='https://www.mdpi.com/2392-7674/10/1/7#:~:text=Matrix%20Gla%20Protein%E2%80%94A%20New%20Marker,has%20been%20described%20in%20numerous')
104. AnnotationURLCitation(end_index=41617, start_index=41467, title='Matrix Gla Protein—A New Marker for Colorectal Cancer Detection? A Systematic Review', type='url_citation', url='https://www.mdpi.com/2392-7674/10/1/7#:~:text=Matrix%20Gla%20Protein%E2%80%94A%20New%20Marker,has%20been%20described%20in%20numerous')
105. AnnotationURLCitation(end_index=42272, start_index=42105, title='Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis? - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10685148/#:~:text=Mgp%20increased%20with%20time%20and,response%20to%20transforming%20growth%20factor')